A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...

The collaboration leverages uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing and regulatory support.

On 25 March, detailed Phase I trial data was published for ESO-T01, AstraZeneca’s in vivo CAR-T therapy, in patients with ...

A mouse study shows CAR-T cells can be engineered in vivo with precise gene editing, a potential breakthrough that could cut ...

The Bay Area In Vivo CAR-T Symposium aims to bring together scientists to discuss the emerging challenges and innovations ...

Etelka is a post-doctoral research fellow exploring aerosol science with biology and engineering.View full profile Etelka is a post-doctoral research fellow exploring aerosol science with biology and ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising ...

Researchers headed by a team at the California Institute of Technology developed an ultrasound-guided 3D printing technique that could make it possible to fabricate medical implants in vivo and ...

In addition to scalability, another opportunity is presented by clinical feasibility and performance. For example, lymphodepletion conditioning, which is a must for ex vivo-engineered CAR-T cells, is ...

Before a drug candidate can be tested in humans, its safety and efficacy must be explored in preclinical studies. These studies can either be ‘in vitro’, Latin for “within the glass” and referring to ...